218 related articles for article (PubMed ID: 34706119)
1. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
Seyrek N; Hollemans E; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Bangma CH; Rietbergen J; Roobol MJ; Schoots IG; van Leenders GJLH
Histopathology; 2022 Feb; 80(3):558-565. PubMed ID: 34706119
[TBL] [Abstract][Full Text] [Related]
2. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
Seyrek N; Hollemans E; Andrinopoulou ER; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Remmers S; Schoots IG; van Leenders GJLH
Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
[TBL] [Abstract][Full Text] [Related]
3. Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.
Kato M; Hirakawa A; Sato H; Hanazawa R; Naito Y; Tochigi K; Sano T; Ishida S; Funahashi Y; Fujita T; Matsukawa Y; Hattori R; Tsuzuki T
Int J Clin Oncol; 2021 Apr; 26(4):764-769. PubMed ID: 33385274
[TBL] [Abstract][Full Text] [Related]
4. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
Epstein JI; Amin MB; Fine SW; Algaba F; Aron M; Baydar DE; Beltran AL; Brimo F; Cheville JC; Colecchia M; Comperat E; da Cunha IW; Delprado W; DeMarzo AM; Giannico GA; Gordetsky JB; Guo CC; Hansel DE; Hirsch MS; Huang J; Humphrey PA; Jimenez RE; Khani F; Kong Q; Kryvenko ON; Kunju LP; Lal P; Latour M; Lotan T; Maclean F; Magi-Galluzzi C; Mehra R; Menon S; Miyamoto H; Montironi R; Netto GJ; Nguyen JK; Osunkoya AO; Parwani A; Robinson BD; Rubin MA; Shah RB; So JS; Takahashi H; Tavora F; Tretiakova MS; True L; Wobker SE; Yang XJ; Zhou M; Zynger DL; Trpkov K
Arch Pathol Lab Med; 2021 Apr; 145(4):461-493. PubMed ID: 32589068
[TBL] [Abstract][Full Text] [Related]
5. Percentage Gleason pattern 4 and PI-RADS score predict upgrading in biopsy Grade Group 2 prostate cancer patients without cribriform pattern.
van der Slot MA; Seyrek N; Kweldam CF; den Bakker MA; Busstra MB; Gan M; Klaver S; Rietbergen JBW; van Leenders GJLH
World J Urol; 2022 Nov; 40(11):2723-2729. PubMed ID: 36190529
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
[TBL] [Abstract][Full Text] [Related]
8. Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.
Hansum T; Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Osanto S; Pelger RCM; van Wezel T; van der Poel H; Bekers E; Helleman J; Remmers S; van Leenders GJLH
Mod Pathol; 2021 Nov; 34(11):2064-2070. PubMed ID: 34175896
[TBL] [Abstract][Full Text] [Related]
9. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
Kweldam CF; Kümmerlin IP; Nieboer D; Steyerberg EW; Bangma CH; Incrocci L; van der Kwast TH; Roobol MJ; van Leenders GJ
Mod Pathol; 2017 Aug; 30(8):1126-1132. PubMed ID: 28530220
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of cribriform size, percentage, and intraductal carcinoma in Gleason score 7 prostate cancer with cribriform Gleason pattern 4.
Chen Z; Pham H; Abreu A; Amin MB; Sherrod AE; Xiao GQ; Aron M
Hum Pathol; 2021 Dec; 118():18-29. PubMed ID: 34543668
[TBL] [Abstract][Full Text] [Related]
11. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores.
Okubo Y; Sato S; Hasegawa C; Koizumi M; Suzuki T; Yamamoto Y; Yoshioka E; Ono K; Washimi K; Yokose T; Kishida T; Miyagi Y
Hum Pathol; 2023 May; 135():99-107. PubMed ID: 36738975
[TBL] [Abstract][Full Text] [Related]
12. Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers.
Iakymenko OA; Lugo I; Briski LM; Nemov I; Punnen S; Kwon D; Pollack A; Stoyanova R; Parekh DJ; Jorda M; Gonzalgo ML; Kryvenko ON
Prostate; 2021 Sep; 81(12):866-873. PubMed ID: 34184782
[TBL] [Abstract][Full Text] [Related]
13. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.
Kweldam CF; Kümmerlin IP; Nieboer D; Verhoef EI; Steyerberg EW; van der Kwast TH; Roobol MJ; van Leenders GJ
Mod Pathol; 2016 Jun; 29(6):630-6. PubMed ID: 26939875
[TBL] [Abstract][Full Text] [Related]
14. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
15. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
van Leenders GJLH; Kweldam CF; Hollemans E; Kümmerlin IP; Nieboer D; Verhoef EI; Remmers S; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ
Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.
Trudel D; Downes MR; Sykes J; Kron KJ; Trachtenberg J; van der Kwast TH
Eur J Cancer; 2014 Jun; 50(9):1610-6. PubMed ID: 24703897
[TBL] [Abstract][Full Text] [Related]
17. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.
Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Helleman J; Roobol MJ; van Leenders GJLH
Mod Pathol; 2019 Jan; 32(1):139-146. PubMed ID: 30349027
[TBL] [Abstract][Full Text] [Related]
18. Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen.
Huang CC; Kong MX; Zhou M; Rosenkrantz AB; Taneja SS; Melamed J; Deng FM
Am J Surg Pathol; 2014 Aug; 38(8):1096-101. PubMed ID: 24832163
[TBL] [Abstract][Full Text] [Related]
19. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
20. Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer.
Czaja RC; Tarima S; Wu R; Palagnmonthip W; Iczkowski KA
Ann Diagn Pathol; 2021 Jun; 52():151725. PubMed ID: 33610958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
